Many pharma companies create DTC efforts around a branded product, but plenty of drugmakers go the disease education route, too. So when is the right time to use each? That all depends on the population a pharma is trying to reach, and as Pfizer found recently, sometimes they can be used simultaneously to get targeted messages across to different patient groups.
Pfizer's mission to expand Lyrica use just hit a couple of roadblocks.
What does Big Pharma like better than a blockbuster? A bigger blockbuster. And that's just what Pfizer ($PFE) might find in its pain and seizure drug Lyrica. Based on early efficacy data, the company
Pfizer has racked up some positive data for Lyrica in Japan. A new study found that fibromyalgia patients saw a statistically significant reduction in their mean pain score after treatment with
Might Lyrica get yet another indication? As Motley Fool notes, the Pfizer drug just passed a trial for neuropathic pain after spinal cord injury. No detailed data was released, but beating out
Call it a win-win deal. Pfizer and Eisai have restructured their Aricept partnership and entered a new co-promotion deal on Lyrica. The deals ward off a court battle over the Alzheimer's treatment
Is fibromyalgia for real? The question keeps popping up, despite the protests of patient advocates and drugmakers alike. Their contention: That they are educating the public in general and medicine
Taking an antidepressant might help assuage the symptoms of fibromyalgia, a new study finds, but experts caution that does not mean that depression is the cause of the condition. Fibromyalgia
Stringent epilepsy drug black-box labeling is likely to worry consumers and drug manufacturers alike, and will bring the total of drugs with a suicide risk warning up to about 35. The new warnings
If the pharma industry were in need of a poster child for indication-happy drug marketing, Cymbalta could be it. The Eli Lilly med is now "the Swiss army knife of drugs," the Indianapolis Star says.